Table 2.
Model Inputs: Drug Unit and Health States and Exacerbation Costs (2021, GBP)
| Generic Name | Dose | Pack Size | Pack Costa | Cost per Dose | Cost per Day | Label Dosing |
| FF/UMEC/VI | 100 μg/62.5 μg/25 μg | 30 | £44.50 | £1.48 | £1.48 | 1 inhalation per day |
| TIO | 18 μg | 30 | £33.50 | £1.12 | £1.12 | 1 inhalation per day |
| Subsequent therapy medications | Weighted average cost per dayb | |||||
| ICS/LABA/LAMA | £1.72 | |||||
| ICS/LABA | £0.87 | |||||
| LAMA/LABA | £1.08 | |||||
| LAMA | £1.02 | |||||
| Health state | Total management cost per year or exacerbationc | |||||
| Moderate to severe (FEV1% predicted 80% to 50%) | £120 | |||||
| Severe (FEV1% predicted <50% to 30%) | £798 | |||||
| Very severe (FEV1% predicted <30%) | £1482 | |||||
| Exacerbation | ||||||
| Moderate | £83 | |||||
| Severe | £2234 | |||||
Notes: aMedication costs were obtained from the British National Formulary.26 bWeighted average cost per day was calculated based on the UK market share (packs sold) of the individual products.28 Where there was more than one pack cost available, the average cost was applied to determine the average daily cost for that therapy. cResource utilization estimates and unit costs for healthcare items in each health state were obtained from a published NICE economic report.27 Unit costs were inflated to 2021 values using the Consumer Price Index data obtained from the Office for National Statistics.29
Abbreviations: FEV1, forced expiratory volume in 1 second; FF, fluticasone furoate; GBP, British Pound; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; NICE, National Institute for Health and Care Excellence; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.